Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 11 January 2018, 10:46 HKT/SGT
Share:
    

Source: Eisai
Eisai Completes Construction of Oral Solid Dose Production Facility at New Suzhou Plant in China

TOKYO, Jan 11, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has completed construction of a new oral solid dose (OSD) production facility and an administration building at the site of its new Suzhou plant located within the Suzhou Industrial Park.

Aiming to further expand its contribution to patients in China, Eisai has been working to establish a new Suzhou plant on a new industrial site more than five times larger than the current Suzhou Plant (OSD production facility) to further strengthen the stable supply chain as well as improve production efficiency.

ECI established a parenteral facility in November 2014, where it manufactures the injection formulation of Methycobal. The newly completed OSD production facility stands three floors aboveground and contains floor space of approximately 20,240 m2, and its production capacity (formulation of approximately 3 billion tablets / packaging for approximately 5 billion tablets per year) is approximately double that of the current Suzhou Plant. Operations are expected to commence in the second half of fiscal 2018, and the new OSD facility will handle the formulation and packaging of oral solid dose products such as Methycobal, Aricept and Pariet for the domestic Chinese market. The current plant will be closed after operations fully commence at the new Suzhou Plant's OSD production facility.

Eisai's business operations in China are one of its core businesses which is third-largest in scale after Japan and the United States. Through the completion of the OSD production facility at the new Suzhou Plant, Eisai seeks to strengthen its in-house domestic production system in China and expand its stable supply chain of high quality pharmaceuticals, contributing to increasing the benefits to patients and their families in China.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Eisai Co., Ltd.
Public Relations Department
+81-3-3817-5120


Jan 11, 2018 10:46 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 6, 2018 09:24 HKT/SGT
Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
Nov 29, 2018 13:48 HKT/SGT
Eisai: MOVICOL Launched in Japan
Nov 28, 2018 10:55 HKT/SGT
Eisai: Primary Endpoint Met in Phase III Clinical Study of Fycompa
Nov 27, 2018 17:02 HKT/SGT
Eisai to Present New Research on Eribulin (Halaven) at 41st Annual San Antonio Breast Cancer Symposium
Nov 23, 2018 07:14 HKT/SGT
Eisai to Present Latest Data on Perampanel at 72nd American Epilepsy Society Annual Meeting
Nov 14, 2018 12:30 HKT/SGT
Eisai Receives "IR Grand Prix Award"
Nov 12, 2018 11:51 HKT/SGT
Eisai Launches Lenvima (Lenvatinib) in China
Nov 9, 2018 08:08 HKT/SGT
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Nov 8, 2018 14:38 HKT/SGT
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence
Nov 8, 2018 08:43 HKT/SGT
Eisai Commences Full-Scale Operation of New Suzhou Plant in China
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: